Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 191 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Locally Advanced Pancreatic Adenocarcinoma Clear all
Completed Phase 1 Interventional

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00003426
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

NCT04292743
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Eryaspase, FOLFIRINOX
Biological · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Minocycline Study in Pancreatic Cancer Patients

NCT01693523
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

NCT00059982
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
perifosine
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Urbana, Illinois • South Bend, Indiana • Des Moines, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

NCT00004190
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions
A2B694, A2B543, xT CDx with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Terminated Phase 1 Interventional

Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

NCT00878657
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting Phase 1 Interventional

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204
View directory record Official record
Conditions
Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions
ASP5834, panitumumab
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting Phase 1 Interventional

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TTI-101, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00376948
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
genistein, erlotinib hydrochloride, gemcitabine hydrochloride
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
21 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 8, 2026, 2:50 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 8, 2026, 2:50 PM EDT
Active, not recruiting Phase 1 Interventional

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

NCT05607953
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
SD-101, anti-PD-1
Drug · Biological
Lead sponsor
TriSalus Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Early Phase 1 Interventional

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

NCT02153450
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
Interventions
metformin hydrochloride, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting Early Phase 1 Interventional

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT07089940
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Withdrawn Phase 1 Interventional

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT06206876
View directory record Official record
Conditions
Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, DDX5 Degrader FL118, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 8, 2026, 2:50 PM EDT
Not yet recruiting Phase 1 Interventional

Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

NCT06217666
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
PCX-12
Drug
Lead sponsor
Haoming (Carl) Qiu
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Not listed Not applicable Interventional

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT00079365
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer

NCT00075686
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
382
States / cities
Mobile, Alabama • Opelika, Alabama • Anchorage, Alaska + 276 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting Phase 1 Interventional

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06673017
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PTM-101
Drug
Lead sponsor
PanTher Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT00305760
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 1 Interventional

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

NCT01908478
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Veliparib, Gemcitabine, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 8, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00408564
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, oxaliplatin, conventional surgery, radiation therapy, Gemcitabine
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 8, 2026, 2:50 PM EDT
Recruiting No phase listed Observational

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

NCT06600906
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 8, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol

NCT01760252
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 8, 2026, 2:50 PM EDT